Patents by Inventor Ulf Eriksson

Ulf Eriksson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5731195
    Abstract: In accordance with this invention, an RPE cell membrane associated protein which has a molecular weight of about 32 kd, as determined by SDS-PAGE, has now been discovered. This protein, referred to an "p32," forms an oligomeric protein complex with the previously characterized p63 protein, a component of the membrane receptor for RBP. A nucleic acid molecule which codes for the p32 protein has also been isolated and sequence analysis shows that the p32 protein belongs to the family of short chain alcohol dehydrogenases, and exhibits 11-cis retinol dehydrogenase activity, the enzyme which catalyzes conversion of 11-cis-retinol into 11-cis retinaldehyde.
    Type: Grant
    Filed: January 20, 1995
    Date of Patent: March 24, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Andras Simon, Ulf Hellman, Christer Wernstedt, Ulf Eriksson
  • Patent number: 5679772
    Abstract: Isolated receptors for lipocalins and retinol binding proteins are disclosed, as are nucleic acid sequences coding for these molecules, and antibodies which bind to these receptors. Various uses of these materials are described as well.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 21, 1997
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Claes Olof B.ang.vik, Ulf Eriksson, Per A. Peterson
  • Patent number: 5607918
    Abstract: VEGF-B polypeptides from the PDGF family of growth factors having the property of promoting mitosis and proliferation of vascular endothelial cells, DNA sequences encoding these polypeptides, pharmaceutical compositions containing them and antibodies which react with them. The VEGF-B polypeptides are useful in stimulating angiogenesis as well as in diagnostic applications.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 4, 1997
    Assignees: Ludwig Institute for Cancer Research, Helsinki University Licensing Ltd. Oy
    Inventors: Ulf Eriksson, Birgitta Olofsson, Kari Alitalo, Katri Pajusola
  • Patent number: 5573939
    Abstract: Isolated receptors for lipocalins and retinol binding proteins are disclosed, as are nucleic acid sequences coding for these molecules, and antibodies which bind to these receptors. Various uses of these materials are described as well.
    Type: Grant
    Filed: February 22, 1994
    Date of Patent: November 12, 1996
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Claes O. B.ang.vik, Ulf Eriksson, Per A. Peterson
  • Patent number: 4711179
    Abstract: An arrangement in a mine which is capable of being neutralized, comprising detecting means (33) operative to detect a neutralization of the mine, and initiator means (3) adapted to initiate detonation of a spotter charge (5) incorporated in the mine in response to the detection of a neutralization, and a spotter (1) which is arranged to be propelled from the mine by said detonator charge to the surface of the ground, in order to disclose the location of the mine. A penetrator (4), which is intended to drive a pathway through the ground to facilitate passage of the spotter (1), is arranged forwardly of the spotter in the mine, as seen in its direction of travel. The spotter (1) is capable of forwardly driving the penetrator (4) during a first phase of the spotter firing sequence; and the arrangement further includes a separating device (9) which is intended to separate the spotter from the penetrator during a second phase of the firing sequence.
    Type: Grant
    Filed: October 17, 1986
    Date of Patent: December 8, 1987
    Assignee: Affarsverket FFV
    Inventors: Sten Sundberg, Stig Risberg, Ulf Eriksson